nach oben

Erschienen in:

01.06.2015 | Central Nervous System and Cognition (SS Spudich, Section Editor)

Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS

verfasst von: Maria M. Bednar, Christa Buckheit Sturdevant, Lauren A. Tompkins, Kathryn Twigg Arrildt, Elena Dukhovlinova, Laura P. Kincer, Ronald Swanstrom

Erschienen in: Current HIV/AIDS Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection occurs throughout the body and can have dramatic physical effects, such as neurocognitive impairment in the central nervous system (CNS). Furthermore, examining the virus that resides in the CNS is challenging due to its location and can only be done using samples collected either at autopsy, indirectly form the cerebral spinal fluid (CSF), or through the use of animal models. The unique milieu of the CNS fosters viral compartmentalization as well as evolution of viral sequences, allowing for new cell types, such as macrophages and microglia, to be infected. Treatment must also cross the blood–brain barrier adding additional obstacles in eliminating viral populations in the CNS. These long-lived infected cell types and treatment barriers may affect functional cure strategies in people on highly active antiretroviral therapy (HAART).

Blackard JT. HIV compartmentalization: a review on a clinically important phenomenon. Curr HIV Res. 2012;10(2):133–42.PubMed

Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 2013;8(3):165–9.PubMed

Arrildt K, Joseph SB, Swanstrom R. The HIV-1 ENV protein: a coat of many colors. Curr HIV/AIDS Rep. 2011;9(1):52–63.

Svicher V, Ceccherini-Silberstein F, Antinori A, Aquaro S, Perno CF. Understanding HIV compartments and reservoirs. Curr HIV/AIDS Rep. 2014;11(2):186–94. doi:10.1007/s11904-014-0207-y.PubMed

Battistini A, Sgarbanti M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses. 2014;6(4):1715–58. doi:10.3390/v6041715.PubMedCentralPubMed

Rossi F, Querido B, Nimmagadda M, Cocklin S, Navas-Martin S, Martin-Garcia J. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology. 2008;5:89. doi:10.1186/1742-4690-5-89.PubMedCentralPubMed

Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, et al. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A. 2006;103(41):15160–5. doi:10.1073/pnas.0605513103.PubMedCentralPubMed

Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology. 2007;367(1):222–34. doi:10.1016/j.virol.2007.05.029.PubMedCentralPubMed

Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003;77(22):12336–45.PubMedCentralPubMed

10.

Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol. 1994;68(7):4643–9.PubMedCentralPubMed

11.

Tang YW, Huong JT, Lloyd Jr RM, Spearman P, Haas DW. Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J Clin Microbiol. 2000;38(12):4637–9.PubMedCentralPubMed

12.

Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with abacavir. AIDS. 2001;15(6):747–51.PubMed

13.

Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol. 2005;79(3):1772–88.PubMedCentralPubMed

14.

Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain J Neurol. 2006;129(Pt 7):1872–83. doi:10.1093/brain/awl136.

15.

Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84(5):2395–407.PubMedCentralPubMed

16.

Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011;7(10):e1002286. doi:10.1371/journal.ppat.1002286.PubMedCentralPubMed

17.

Sturdevant CB, Dow A, Jabara CB, Joseph SB, Schnell G, Takamune N, et al. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog. 2012;8(12):e1003094. doi:10.1371/journal.ppat.1003094.PubMedCentralPubMed

18.••

Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol. 2014;88(4):1858–69. This paper shows a direct correlation between the enhanced ability of macrophage-tropic viruses to use low levels of CD4, which is restrictive for T cell-tropic viruses, and the lower levels of CD4 expressed on MDM compared to memory T cells. This highlights receptor usage and not coreceptor use as the main determinant of macrophage tropism. PubMedCentralPubMed

19.

Cu-Uvin S, Snyder B, Harwell JI, Hogan J, Chibwesha C, Hanley D, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr. 2006;42(5):584–7. doi:10.1097/01.qai.0000229997.52246.95.PubMed

20.

Homans J, Christensen S, Stiller T, Wang CH, Mack W, Anastos K, et al. Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr. 2012;60(1):99–110. doi:10.1097/QAI.0b013e31824aeaaa.PubMedCentralPubMed

21.

Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29. doi:10.1126/scitranslmed.3001888.PubMedCentralPubMed

22.

Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS. 2010;24(16):2489–97. doi:10.1097/QAD.0b013e32833e5043.PubMed

23.

Spear GT, Zariffard MR, Chen HY, Anzinger JJ, Anastos K, Rusine J, et al. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retrovir. 2008;24(7):973–6. doi:10.1089/aid.2008.0004.PubMedCentralPubMed

24.

Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17(4):455–80. doi:10.1097/01.aids.0000042970.95433.f9.PubMed

25.

Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358(9293):1593–601. doi:10.1016/S0140-6736(01)06653-3.PubMed

26.

Kroodsma KL, Kozal MJ, Hamed KA, Winters MA, Merigan TC. Detection of drug resistance mutations in the human immunodeficiency virus type 1 (HIV-1) pol gene: differences in semen and blood HIV-1 RNA and proviral DNA. J Infect Dis. 1994;170(5):1292–5.PubMed

27.

Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen: an isolated virus reservoir. Lancet. 1997;350(9085):1141. doi:10.1016/S0140-6736(97)24042-0.PubMed

28.

Byrn RA, Kiessling AA. Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. J Reprod Immunol. 1998;41(1–2):161–76.PubMed

29.

Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol. 1996;70(5):3098–107.PubMedCentralPubMed

30.

Delwart EL, Mullins JI, Gupta P, Learn Jr GH, Holodniy M, Katzenstein D, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998;72(1):617–23.PubMedCentralPubMed

31.

Diem K, Nickle DC, Motoshige A, Fox A, Ross S, Mullins JI, et al. Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res Hum Retrovir. 2008;24(4):561–71. doi:10.1089/aid.2007.0115.PubMed

32.

Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol. 2009;83(8):3556–67. doi:10.1128/JVI. 02132-08.PubMedCentralPubMed

33.

Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, et al. HIV-1 populations in semen arise through multiple mechanisms. PLoS Pathog. 2010;6(8):e1001053. doi:10.1371/journal.ppat.1001053.PubMedCentralPubMed

34.

Bull M, Learn G, Genowati I, McKernan J, Hitti J, Lockhart D, et al. Compartmentalization of HIV-1 within the female genital tract is due to monotypic and low-diversity variants not distinct viral populations. PLoS One. 2009;4(9):e7122. doi:10.1371/journal.pone.0007122.PubMedCentralPubMed

35.

Kemal KS, Foley B, Burger H, Anastos K, Minkoff H, Kitchen C, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A. 2003;100(22):12972–7. doi:10.1073/pnas.2134064100.PubMedCentralPubMed

36.•

Bull ME, Heath LM, McKernan-Mullin JL, Kraft KM, Acevedo L, Hitti JE, et al. Human immunodeficiency viruses appear compartmentalized to the female genital tract in cross-sectional analyses but genital lineages do not persist over time. J Infect Dis. 2013;207(8):1206–15. doi:10.1093/infdis/jit016. Shows the transient nature of comparmentalization in the female genital tract over a period of 1.5-4.5 years. PubMedCentralPubMed

37.•

Price RW, Spudich SS, Peterson J, Joseph S, Fuchs D, Zetterberg H, et al. Evolving character of chronic central nervous system HIV infection. Semin Neurol. 2014;34(1):7–13. doi:10.1055/s-0034-1372337. The paper is a current review of the history of HIV-associated dementia (HAD). PubMedCentralPubMed

38.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011;204(5):753–60. doi:10.1093/infdis/jir387.PubMedCentralPubMed

39.

Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. PLoS Pathog. 2015;11(3):e1004720. doi:10.1371/journal.ppat.1004720.

40.

Harrington PR, Schnell G, Letendre SL, Ritola K, Robertson K, Hall C, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009;23(8):907–15. doi:10.1097/QAD.0b013e3283299129.PubMedCentralPubMed

41.

Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials. 2003;4(2):137–43.PubMed

42.

Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, et al. Comparison of viral Env proteins from acute and chronic infections of subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013. doi:10.1128/JVI. 03577-12.PubMedCentralPubMed

43.

Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol. 2011;85(16):8253–62.PubMedCentralPubMed

44.

Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42(9):1736–9.PubMed

45.

Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis: Off Pub Infect Dis Soc Am. 2000;30(6):962–5. doi:10.1086/313810.

46.

Pilcher CD, Shugars DC, Fiscus SA, Miller WC, Menezes P, Giner J, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001;15(7):837–45.PubMed

47.

Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16(8):1119–29.PubMed

48.

Taiwo BO, Hicks CB. Primary human immunodeficiency virus. South Med J. 2002;95(11):1312–7.PubMed

49.

Stekler J, Collier AC. Primary HIV infection. Curr HIV/AIDS Rep. 2004;1(2):68–73.PubMed

50.

Heaton RK, Clifford DB, Franklin Jr DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75(23):2087–96. doi:10.1212/WNL.0b013e318200d727.PubMedCentralPubMed

51.

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16. doi:10.1007/s13365-010-0006-1.PubMedCentralPubMed

52.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther. 2005;10(6):701–7.PubMed

53.

Agsalda-Garcia M, Shiramizu B, Melendez L, Plaud M, Liang CY, Wojna V. Different levels of HIV DNA copy numbers in cerebrospinal fluid cellular subsets. J Health Care Poor Underserved. 2013;24(4 Suppl):8–16. doi:10.1353/hpu.2014.0010.PubMed

54.

Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–25. doi:10.1086/657342.PubMedCentralPubMed

55.

Spudich SS. CROI 2014: neurologic complications of HIV infection. Top Antivir Med. 2014;22(2):594–601.PubMed

56.

Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013;207(11):1703–12. doi:10.1093/infdis/jit088.PubMedCentralPubMed

57.

Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(6510):117–22.PubMed

58.

Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123–6.PubMed

59.

Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54(4):927–36.PubMed

60.

Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retrovir. 2000;16(15):1491–502. doi:10.1089/088922200750006010.PubMed

61.

Olivieri KC, Agopian KA, Mukerji J, Gabuzda D. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retrovir. 2010;26(4):495–500. doi:10.1089/aid.2009.0257.PubMedCentralPubMed

62.

Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300.PubMed

63.

Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 2009;5(4):e1000395.PubMedCentralPubMed

64.

Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev. 2013;254(1):102–13. doi:10.1111/imr.12068.PubMedCentralPubMed

65.

Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci. 2002;25:537–62. doi:10.1146/annurev.neuro.25.112701.142822.PubMed

66.

Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9(6):552–8. doi:10.1097/COH.0000000000000108.PubMed

67.•

Chauhan A, Mehla R, Vijayakumar TS, Handy I. Endocytosis-mediated HIV-1 entry and its significance in the elusive behavior of the virus in astrocytes. Virology. 2014;456–457:1–19. doi:10.1016/j.virol.2014.03.002. In cell culture, this paper shows infection of astrocytes is primarily though endocytosis. PubMed

68.

Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5∆32/∆32 stem cell transplantation. Blood. 2011;117(10):2791–9. doi:10.1182/blood-2010-09-309591.PubMed

69.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8. doi:10.1056/NEJMoa0802905.PubMed

70.

Yukl SA, Boritz E, Busch M, Bentsen C, Chun TW, Douek D, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013;9(5):e1003347. doi:10.1371/journal.ppat.1003347.PubMedCentralPubMed

71.

Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science. 2010;329(5988):174–80. doi:10.1126/science.1191047.PubMed

72.

International ASSWGoHIVC, Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607–14. doi:10.1038/nri3262.

73.

Deeks SG. HIV: shock and kill. Nature. 2012;487(7408):439–40. doi:10.1038/487439a.PubMed

74.

Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak Jr M, Coffin JM, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014;111(19):7078–83. doi:10.1073/pnas.1402873111.PubMedCentralPubMed

75.••

Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540–51. doi:10.1016/j.cell.2013.09.020. This paper nicely illustrates how important it is to have continued progress in all areas of HIV research, including viral measurement. It highlights the difference in reservoir size between induced latent provirus, and intact noninduced proviruses, and how that may be effecting cure strategies. PubMedCentralPubMed

76.

Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. 2009;23(14):1799–806. doi:10.1097/QAD.0b013e32832ec1dc.PubMed

77.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482–5. doi:10.1038/nature11286.PubMedCentralPubMed

78.

Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis: Off Pub Infect Dis Soc Am. 2014;58(6):883–90. doi:10.1093/cid/cit813.

79.

Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine. 2009;4(5):557–74. doi:10.2217/nnm.09.38.PubMedCentralPubMed

80.

Nowacek A, Kosloski LM, Gendelman HE. Neurodegenerative disorders and nanoformulated drug development. Nanomedicine. 2009;4(5):541–55. doi:10.2217/nnm.09.37.PubMedCentralPubMed

81.

Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine. 2009;4(8):903–17. doi:10.2217/nnm.09.71.PubMedCentralPubMed

82.

Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med Pub Int AIDS Soc USA. 2010;18(2):45–55.

83.

Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417(6884):95–8. doi:10.1038/417095a.PubMed

84.

Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol. 2004;78(3):1160–8.PubMedCentralPubMed

85.

Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol. 2009;83(16):8208–20. doi:10.1128/JVI. 00296-09.PubMedCentralPubMed

86.

Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E. Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol. 2010;84(8):4100–4. doi:10.1128/JVI. 02068-09.PubMedCentralPubMed

87.

Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118(9):681–8.PubMed

88.

Blaak H, van’t Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A. 2000;97(3):1269–74.PubMedCentralPubMed

89.

Ho SH, Shek L, Gettie A, Blanchard J, Cheng-Mayer C. V3 loop-determined coreceptor preference dictates the dynamics of CD4+ -T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol. 2005;79(19):12296–303. doi:10.1128/JVI. 79.19.12296-12303.2005.PubMedCentralPubMed

90.

Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci U S A. 2004;101(33):12324–9. doi:10.1073/pnas.0404620101.PubMedCentralPubMed

91.

Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, et al. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002;76(12):6277–92. doi:10.1128/jvi. 76.12.6277-6292.2002.PubMedCentralPubMed

92.

Martin-Garcia J, Cao W, Varela-Robena A, Plassmeyer ML, Gonzalez-Scarano F. HIV-1 tropism for the central nervous system: brain-denved envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology. 2006;346(1):169–79. doi:10.1016/j.virol.2005.10.031.PubMed

93.

Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J, Ankghuambom C, Brown R, et al. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J Virol. 2006;80(13):6324–32. doi:10.1128/jvi. 02328-05.PubMedCentralPubMed

94.

Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008;5:5. doi:10.1186/1742-4690-5-5.PubMedCentralPubMed

95.

96.

Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, et al. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol. 2011;85(9):4330–42. doi:10.1128/JVI. 00106-11.PubMedCentralPubMed

97.

Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A. 1999;96(9):5215–20.PubMedCentralPubMed

98.

Harrington PR, Nelson JAE, Kitrinos KM, Swanstrom R. Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection. J Virol. 2007;81(10):5413–7. doi:10.1128/jvi. 02554-06.PubMedCentralPubMed

99.

Milich L, Margolin BH, Swanstrom R. Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology. 1997;239(1):108–18. doi:10.1006/viro.1997.8821.PubMed

100.

De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol. 1992;66(11):6777–80.PubMedCentralPubMed

101.

Evans DT, Silvestri G. Nonhuman primate models in AIDS research. Curr Opin HIV AIDS. 2013;8(4):255–61. doi:10.1097/COH.0b013e328361cee8.PubMedCentralPubMed

102.

Gorantla S, Makarov E, Finke-Dwyer J, Castanedo A, Holguin A, Gebhart CL, et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol. 2010;177(6):2938–49. doi:10.2353/ajpath.2010.100536.PubMedCentralPubMed

103.

Dash PK, Gorantla S, Gendelman HE, Knibbe J, Casale GP, Makarov E, et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci Off J Soc Neurosci. 2011;31(9):3148–57. doi:10.1523/JNEUROSCI. 5473-10.2011.

104.

Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45. doi:10.3389/fncel.2013.00045.PubMedCentralPubMed

105.

Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, Elkins WR, et al. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol. 1997;71(2):1608–20.PubMedCentralPubMed

106.

Dang Q, Goeken RM, Brown CR, Plishka RJ, Buckler-White A, Byrum R, et al. Adaptive evolution of simian immunodeficiency viruses isolated from 2 conventional-progressor macaques with encephalitis. J Infect Dis. 2008;197(12):1695–700. doi:10.1086/588671.PubMedCentralPubMed

107.

Matsuda K, Brown CR, Foley B, Goeken R, Whitted S, Dang Q, et al. Laser capture microdissection assessment of virus compartmentalization in the central nervous systems of macaques infected with neurovirulent simian immunodeficiency virus. J Virol. 2013;87(16):8896–908. doi:10.1128/JVI. 00874-13.PubMedCentralPubMed

108.

Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, Wood C. HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neurovirol. 1999;5(6):670–7.PubMed

109.

Burkala EJ, He J, West JT, Wood C, Petito CK. Compartmentalization of HIV-1 in the central nervous system: role of the choroid plexus. AIDS. 2005;19(7):675–84.PubMed

110.

Chen MF, Westmoreland S, Ryzhova EV, Martin-Garcia J, Soldan SS, Lackner A, et al. Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology. J Neurovirol. 2006;12(2):73–89. doi:10.1080/13550280600654565.PubMed

111.

Babas T, Dewitt JB, Mankowski JL, Tarwater PM, Clements JE, Zink MC. Progressive selection for neurovirulent genotypes in the brain of SIV-infected macaques. AIDS. 2006;20(2):197–205. doi:10.1097/01.aids.0000198078.24584.21.PubMed

112.

Harrington PR, Connell MJ, Meeker RB, Johnson PR, Swanstrom R. Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection. J Infect Dis. 2007;196(7):1058–67. doi:10.1086/520819.PubMed

113.

Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, Allan JS. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J Virol. 2001;75(5):2262–75. doi:10.1128/JVI. 75.5.2262-2275.2001.PubMedCentralPubMed

Titel: Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS
verfasst von: Maria M. Bednar
Christa Buckheit Sturdevant
Lauren A. Tompkins
Kathryn Twigg Arrildt
Elena Dukhovlinova
Laura P. Kincer
Ronald Swanstrom
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 2/2015
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-015-0265-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions

Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets

Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention Approaches

Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

Implementation Research for the Prevention of Mother-to-Child HIV Transmission in Sub-Saharan Africa: Existing Evidence, Current Gaps, and New Opportunities